July 2024 Content Release Copied

07/25/20242024 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

Problem Groups

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

ER status is now available for Uterine Cancer, Sarcoma with the following documentation points:

  • Positive
  • Negative
  • Unknown

PR status is now available for Uterine Cancer, Sarcoma with the following documentation points:

  • Positive
  • Negative
  • Unknown

ALK is now available for Uterine Cancer, Sarcoma with the following documentation points:

  • Positive
  • Negative
  • Equivocal
  • Unknown

Procedures

Additions

The following new item is available for documentation in Procedures and appear in the Charge Capture Report (CCR):

Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions

Search Alias: STEREOTACTIC RADIATION TX MANAGEMENT, 2-5 FRACTIONS (77435)

Lab Analytes & Panels

Additions

  • ADAMTS13 inhibitor
  • ADAMTS13 inhibitor panel
  • ADAMTS13 inhibitory comment
  • AFP/HCG tumor marker panel
  • Angiotensin converting enzyme panel
  • Brain NGS fusion panel
  • Brain NGS Fusion panel (NeoGenomics)
  • BRCA1 and BRCA2 focus panel (Germline)
  • BRCA1 and BRCA2 focus panel (Germline) (NeoGenomics)
  • BRCA1 single gene (Germline)
  • BRCA1 single gene (Germline) (NeoGenomics)
  • BRCA2 single gene (Germline)
  • BRCA2 single gene (Germline) (NeoGenomics)
  • Breast NGS fusion panel
  • Breast NGS fusion panel (NeoGenomics)
  • C-KIT (D816V)
  • Calculi mass, urine, mg
  • Cholangio/Pancreatic carcinoma NGS fusion panel
  • Cholangio/Pancreatic carcinoma NGS fusion panel (NeoGenomics)
  • Chromosomal microarray, hematologic disorders additional information
  • Chromosomal microarray, hematologic disorders interpretation
  • Chromosomal microarray, hematologic disorders method
  • Chromosomal microarray, hematologic disorders nomenclature
  • Chromosomal microarray, hematologic disorders panel
  • Chromosomal microarray, hematologic disorders reason for referral
  • Chromosomal microarray, hematologic disorders released by
  • Chromosomal microarray, hematologic disorders result
  • Chromosomal microarray, hematologic disorders result summary
  • Chromosomal microarray, hematologic disorders specimen
  • Colorectal cancer focus panel (Germline)
  • Colorectal cancer focus panel (Germline) (NeoGenomics)
  • Colorectal NGS fusion panel
  • Colorectal NGS fusion panel (NeoGenomics)
  • Copper, random urine panel
  • Dopamine, pmol/L
  • Drug monitoring, fentanyl, screen urine panel
  • Epinephrine, pmol/L
  • Ewing Sarcoma NGS fusion panel
  • Ewing Sarcoma NGS fusion panel (NeoGenomics)
  • Full comprehensive cancer panel (Germline)
  • Full comprehensive cancer panel (Germline) (NeoGenomics)
  • Full focus cancer panel (Germline)
  • Full focus cancer panel (Germline) (NeoGenomics)
  • InVisionFirst(R)-lung liquid biopsy
  • InVisionFirst(R)-lung liquid biopsy (NeoGenomics)
  • Lung Complete NGS fusion panel
  • Lung Complete NGS fusion panel (NeoGenomics)
  • Lung Limited NGS fusion panel
  • Lung Limited NGS fusion panel (NeoGenomics)
  • Myoglobin, urine panel
  • Myoglobin, urine, ng/mL
  • Neo Comprehensive – solid tumor
  • Neo Comprehensive – solid tumor (NeoGenomics)
  • Neo Comprehensive – solid tumor (plus PD-L1)
  • Neo Comprehensive – solid tumor (plus PD-L1) (NeoGenomics)
  • NeoTYPE(R) cholangiocarcinoma profile
  • NeoTYPE(R) cholangiocarcinoma profile (NeoGenomics)
  • NeoTYPE(R) DNA & RNA – brain
  • NeoTYPE(R) DNA & RNA – brain (molecular only, plus MGMT gene promoter methylation analysis)
  • NeoTYPE(R) DNA & RNA – brain (molecular only, plus MGMT gene promoter methylation analysis) (NeoGenomics)
  • NeoTYPE(R) DNA & RNA – brain (NeoGenomics)
  • NeoTYPE(R) DNA & RNA – brain (plus MGMT gene promoter methylation analysis)
  • NeoTYPE(R) DNA & RNA – brain (plus MGMT gene promoter methylation analysis) (NeoGenomics)
  • NeoTYPE(R) DNA & RNA – lung
  • NeoTYPE(R) DNA & RNA – lung (NeoGenomics)
  • NeoTYPE(R) DNA & RNA – lung (plus PD-L1)
  • NeoTYPE(R) DNA & RNA – lung (plus PD-L1) (NeoGenomics)
  • NeoTYPE(R) HRR profile
  • NeoTYPE(R) HRR profile (NeoGenomics)
  • NeoTYPE(TM) gastric tumor profile (MMR Opt Out)
  • NeoTYPE(TM) gastric tumor profile (MMR Opt Out) (NeoGenomics)
  • NeoTYPE(TM) ovarian tumor profile (plus FOLR1)
  • NeoTYPE(TM) ovarian tumor profile (plus FOLR1) (NeoGenomics)
  • Norepinephrine, pmol/L
  • Rhabdomyosarcoma NGS fusion panel
  • Rhabdomyosarcoma NGS fusion panel (NeoGenomics)
  • Salivary gland NGS fusion panel
  • Salivary gland NGS fusion panel (NeoGenomics)
  • Sarcoma comprehensive NGS fusion panel
  • Sarcoma comprehensive NGS fusion panel (NeoGenomics)
  • SLL, FISH panel tissue
  • SLL, FISH panel, tissue panel
  • T-Cell receptor gene rearrangement by NGS panel
  • Targeted solid tumor NGS fusion panel
  • Targeted solid tumor NGS fusion panel (NeoGenomics)
  • TCR gamma, NGS
  • Thyroid NGS fusion panel
  • Thyroid NGS fusion panel (NeoGenomics)
  • TSH cascade panel
  • TSH reflex cascade, uIU/mL
  • Universal solid tumor NGS fusion panel
  • Universal solid tumor NGS fusion panel (NeoGenomics)

Medications

Additions

  • ABBV-383 invest IV
  • BBO-10203 invest Oral
  • CBX-12 invest IV
  • CHS-388 invest IV
  • CT7439 invest Oral
  • CTIM-76 invest IV
  • GSK5764227 invest IV
  • HMPL-523 invest Oral
  • INBRX-106 invest IV
  • KITE-363 invest IV
  • KITE-753 invest IV
  • OBI-992 invest IV
  • OKI-219 invest Oral
  • Rilvegostomig invest IV
  • STP938 invest Oral
  • TTX-MC138 invest IV
  • VET3-TGI invest IV
  • VET3-TGI invest Intratumoral
  • Ziftomenib invest (KO-539 invest Oral)

Updates

Medication Update
Cholecalciferol Oral Added sigs and instructions
Danicopan Oral
  • Added maximum single dose
  • Updated sigs and instructions
  • Changed default form
Eltrombopag Oral (Alvaiz)
  • Added maximum single dose
  • Updated sigs and instructions
Hyaluronidase (Bovine) Intradermal Added sigs and instructions
Imetelstat IV
  • Added sigs and instructions
  • Added maximum single dose
Nogapendekin alfa inbakicept-pmln Intravesical
  • Added maximum single dose
  • Updated quick sigs and instructions
  • New default sigs available: 400 mcg intravesically once; quantity sufficient for 6 week
Phesgo (Pertuzumab-Trastuzumab- Hyaluronidase-zzxf Subcutaneous 1200 mg-600 mg-30,000 unit/15 mL) Updated instructions
Phesgo (Pertuzumab-Trastuzumab- Hyaluronidase-zzxf Subcutaneous 600 mg-600 mg-20,000 unit/10 mL)   Updated instructions
STRO-002 invest IV Added sigs and instructions

Regimen Library

Premedication & Dexamethasone Prescription Update for Daratumumab-containing Regimens

To improve ease of ordering dexamethasone in all daratumumab combination therapy regimens, dexamethasone prescriptions will be streamlined by combining pre- and post-daratumumab dexamethasone into a single dose (based on corticosteroid dosing intent for each regimen).

To reduce chair time and streamline infusion clinic workflows, in all daratumumab-containing regimens the following pre-checked premedications will stop after the 3rd daratumumab dose when risk of administration-related reactions is low. Pre-medications after the 3rd daratumumab dose will be available but not pre-checked.

  • Combination therapy regimen premedications: acetaminophen and diphenhydramine
  • Monotherapy regimen premedications: acetaminophen, diphenhydramine, and dexamethasone

Additions

Regimen Name Diagnosis
Deferasirox (Jadenu) Q30D (Transfusional Iron Overload) All Problems
Durvalumab + Paclitaxel + Carboplatin Q21D Uterine Cancer (Parent)
Imatinib Q30D (Melanoma) Melanoma, Skin
Imetelstat Q28D Myelodysplastic Syndrome (MDS)
Methotrexate HD + Rituximab IV D8 Q14D (Part 1 of 2: Induction) Brain Tumor (Parent)
Methotrexate HD + Rituximab IV D8 Q28D (Part 2 of 2: Consolidation) Brain Tumor (Parent)
Pembrolizumab (Dose Banding) + Gemcitabine D1,8,22,29 + Vinorelbine D1,8,22,29 + Liposomal Doxorubicin D1,8,22,29 (GVD) Q42D Lymphoma, Hodgkin (HL)
Polatuzumab vedotin D1 + Rituximab IV D2 + CHP D2 Q21D (6 cycles) (Immunotherapy Split) fb Rituximab IV Q21D (2 cycles) Lymphoma, Non-Hodgkin (NHL) (Parent)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • Amyloidosis
  • Bile Duct Cancer (Parent)
  • Bladder Cancer
  • Cutaneous Carcinoma, Squamous Cell
  • Gallbladder Cancer
  • Gastrointestinal Stromal Tumor (Parent)
  • Hepatocellular Carcinoma
  • Leukemia, Acute Lymphocytic (ALL)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Multiple Myeloma (MM)
  • Mycosis Fungoides/Sezary Syndrome
  • Pancreatic Cancer
  • Primary Cutaneous Lymphoma
  • Renal Pelvis and Ureter Cancer
  • Solid Tumors (Parent) (including Solid Other/HL)
  • Urethral Cancer
  • Uterine Cancer (Parent)

Renames

Previous Name New Name
Daratumumab IV Q7D (Part 1 of 3) Daratumumab IV C1-2 D1,8,15,22 fb C3-6 D1,15 fb C7-12 D1 Q28D
Daratumumab IV Q7D (Part 1 of 3: C1 Split Dosing) Daratumumab IV C1-2 D1,8,15,22 fb C3-6 D1,15 fb C7-12 D1 Q28D (C1 Split Dosing)
Hyper-CVAD/HD Methotrexate + Cytarabine Q42D (ALL) Hyper-CVAD alternating with Methotrexate HD + Cytarabine Q42D (ALL)
Hyper-CVAD/HD Methotrexate + Cytarabine Q42D (NHL) Hyper-CVAD alternating with Methotrexate HD + Cytarabine Q42D (NHL)
Imatinib Q30D (GIST, Melanoma) Imatinib Q30D (GIST)
Rituximab IV D1,22 + Hyper CVAD/HD Methotrexate + Cytarabine Q42D Rituximab IV D1,22 + Hyper-CVAD alternating with Methotrexate HD + Cytarabine Q42D

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Adalimumab-fkjp Subcutaneous J3590 per 20 mg
Glycopyrrolate-neostigmine IV J3490 per 3 mL
Hyaluronidase (Human Recomb) Intradermal J3473 per 150 units
Imetelstat (Rytelo) IV J9999 per

  • 47 mg
  • 188 mg
Influenza Virus Vaccine IM Tri-Split (36 months & older) J3590 per 0.5 mL
Influenza Virus Vaccine IM Tri-Split (6 months & older) J3590 per 0.5 mL
Influenza virus vaccine IM Tri-Split (6 months & older) Cell Derived J3590 per 0.5 mL
Influenza Virus Vaccine IM Tri-Split (6 months & older) J3590 per 0.5 mL
Pneumococcal 21-val conj-dip crm (PF) IM J3590 per 0.5 mL
Posaconazole IV J3490 per 300 mg
RSV vaccine, preF, mRNA (PF) IM 90683 per 0.5 mL
Tocilizumab-aazg Subcutaneous J3590 per 162 mg